Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amenamevir + montelukast
- Development stage
- Phase 1
- Lead developer
- Maruho
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination consists of **amenamevir** (formerly ASP2151), a small molecule antiviral that inhibits the herpesvirus helicase-primase complex and is approved in Japan for the treatment of herpes zoster and herpes simplex, together with **montelukast**, a leukotriene receptor antagonist used for the treatment and prevention of asthma and allergic rhinitis. The rationale for their combination in clinical research is to study potential drug-drug interactions, particularly the effect of amenamevir on montelukast metabolism via CYP2C8 inhibition, which increases plasma concentrations of montelukast by approximately 22%. There is no clinical indication for combined use outside interaction studies[1][3][4][5][6].
- Other names
- ASP2151 + montelukastamenamevir + montelukast
02
Targets
CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)HPC (Viral helicase-primase complex)Herpes simplex virus type 2 helicase-primase complex (UL5/UL52/UL8)
Beyond the preview
Go deeper on amenamevir + montelukast.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amenamevir + montelukast.